Testosterone propionate

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Testosterone propionate

Short-acting testosterone ester, half-life around two to three days, requiring frequent injection.

Evidence category: Reference only. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Testosterone propionate is a short-acting ester of testosterone. The linked sources are review articles: one revisits the medicinal use of testosterone and related steroids, the other reviews testosterone replacement and the prostate. They describe therapeutic uses and safety questions for this drug class rather than trials of propionate itself. This is general reference reading, not trial evidence for this particular ester.

Benefits reported in the imported source

• Review articles describe therapeutic uses for testosterone and related steroids as a class

Risks and limits

• The sources are reviews of the drug class, not trials of this short-acting ester
• The same reviews raise open safety questions, including effects on the prostate

Source bottom line: A short-acting testosterone ester backed here by class-level reviews, not trials of the ester itself.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 19.2 hours. Published ester PK Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Medicinal Use of Testosterone and Related Steroids Revisited (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• The effects of testosterone replacement therapy on the prostate: a clinical perspective (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• DailyMed: testosterone propionate